Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
Status:
Unknown status
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Patients with cutaneous T cell lymphoma experience refractory and progressive disease despite
current treatment, necessitating chronic disease management. In addition, there needs to be
greater emphasis on combination treatment, which correlates with increased response rate,
more rapid onset of response, and decreased side effect profile compared to monotherapy. The
goal for the use of Lenalidomide as an adjuvant treatment in patients with refractory
cutaneous T cell lymphoma is to increase response rates, maintain a durable long-term
response, relieve associated symptoms, and minimize toxic side effects.